• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    OmniAb Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    1/30/26 4:04:54 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $OABI alert in real time by email
    oabi-20260130
    FALSE000184625312/31Nasdaq00018462532026-01-302026-01-300001846253us-gaap:CommonStockMember2026-01-302026-01-300001846253us-gaap:WarrantMember2026-01-302026-01-30

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    ______________
    FORM 8-K
    ______________
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): January 30, 2026

    OMNIAB, INC.
    (Exact Name of Registrant as Specified in Its Charter)
    Delaware001-4072098-1584818
    (State or other jurisdiction of
    incorporation or organization)
    (Commission File Number)(I.R.S. Employer
    Identification No.)
    5980 Horton Street, Suite 600
    Emeryville
    CA94608
    (Address of principal executive offices)(Zip Code)
    (510) 250-7800
    (Registrant’s Telephone Number, Including Area Code)
    N/A
    (Former Name or Former Address, if Changed Since Last Report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    o
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    o
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    o
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    o
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, par value $0.0001 per shareOABIThe Nasdaq Global Market
    Warrants to purchase common stockOABIW
    The Nasdaq Capital Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☑
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
    On January 30, 2026, the Board of Directors (the “Board”) of OmniAb, Inc. (the “Company”) approved and adopted amended and restated bylaws (the “Amended and Restated Bylaws”), which became effective the same day. Among other things, the amendments effected by the Amended and Restated Bylaws:
    •address the universal proxy rules adopted by the U.S. Securities and Exchange Commission, by clarifying that no person may solicit proxies in support of a director nominee other than the Board’s nominees unless such person has complied with Rule 14a-19 under the Securities Exchange Act of 1934, as amended, including applicable notice and solicitation requirements; and
    •modernize and enhance procedural mechanics and disclosure requirements in connection with stockholder nominations of directors and submissions of proposals regarding other business at stockholder meetings, including requiring additional background information and disclosures regarding proposing stockholders, proposed nominees and business, and other persons related to a stockholder’s solicitation of proxies, such as information about the ownership of securities of the Company.
    The Amended and Restated Bylaws also include certain technical, modernizing and clarifying changes.
    The foregoing description of the Amended and Restated Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended and Restated Bylaws attached hereto as Exhibit 3.1 (clean version) and Exhibit 3.2 (marked version), which are incorporated herein by reference.
    Item 9.01 Financial Statements and Exhibits.
    (d)Exhibits.
    Exhibit No.Description
    3.1
    Amended and Restated Bylaws, effective as of January 30, 2026 (clean version)
    3.2
    Amended and Restated Bylaws (marked version)
    104
    Cover Page Interactive Data File (embedded within Inline XBRL document)



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    OMNIAB, INC.
    Date: January 30, 2026
    By:
    /s/ Charles S. Berkman
    Name: Charles S. Berkman
    Title: Chief Legal Officer and Secretary

    Get the next $OABI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OABI

    DatePrice TargetRatingAnalyst
    11/29/2023$6.00Outperform
    RBC Capital Mkts
    4/21/2023$8.00Buy
    The Benchmark Company
    4/13/2023$10.00Buy
    Craig Hallum
    2/22/2023$10.00Outperform
    Cowen
    2/13/2023$11.00Buy
    H.C. Wainwright
    More analyst ratings

    $OABI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Berkman Charles S converted options into 18,750 shares and sold $16,541 worth of shares (9,673 units at $1.71), increasing direct ownership by 2% to 392,700 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    2/18/26 6:36:13 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Executive VP, Finance and CFO Gustafson Kurt A converted options into 18,750 shares and sold $15,905 worth of shares (9,301 units at $1.71), increasing direct ownership by 4% to 268,851 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    2/18/26 6:35:30 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    President and CEO Foehr Matthew W converted options into 58,333 shares and sold $52,742 worth of shares (30,843 units at $1.71), increasing direct ownership by 0.63% to 4,403,277 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    2/18/26 6:34:48 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    SEC Filings

    View All

    SEC Form 144 filed by OmniAb Inc.

    144 - OmniAb, Inc. (0001846253) (Subject)

    2/17/26 4:33:03 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 144 filed by OmniAb Inc.

    144 - OmniAb, Inc. (0001846253) (Subject)

    2/17/26 4:29:57 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 144 filed by OmniAb Inc.

    144 - OmniAb, Inc. (0001846253) (Subject)

    2/17/26 4:27:02 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OmniAb to Participate at the Leerink Partners Global Healthcare Conference

    OmniAb, Inc. (NASDAQ:OABI) today announced that management will participate at the Leerink Global Healthcare Conference taking place March 8-11, 2026, at the W South Beach in Miami. Management will present a corporate overview on Tuesday, March 10th at 3:40 p.m. Eastern time and will hold one-on-one meetings with investors registered for the event. Investors interested in scheduling a meeting with OmniAb management should contact their Leerink Partners representative, or email [email protected]. About OmniAb® OmniAb licenses cutting edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation th

    2/24/26 8:00:00 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OmniAb to Report Fourth Quarter 2025 Financial Results on March 4

    OmniAb, Inc. (NASDAQ:OABI) will report financial results for the quarter and year ended December 31, 2025, after the close of the U.S. financial markets on Wednesday, March 4, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss fourth quarter 2025 financial results and business updates       Date:   Wednesday, March 4, 2026       Time:   4:30 p.m. Eastern time (1:30 p.m. Pacific time)       Phone:   U.S. (800) 549-8228    

    2/19/26 8:00:00 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies

    First and only transgenic chicken platform engineered to express ultralong CDRH3 domains on a human antibody framework broadens therapeutic opportunities beyond conventional antibodies OmniUltra Virtual Investor Event begins at 5:00 p.m. Eastern time today OmniAb, Inc. (NASDAQ:OABI) announces the launch of its new OmniUltra™ platform, the industry's first and only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at the 2025 Antibody Engineering & Therapeutics (AET) Conference underway in San Diego. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215018419/en/ OmniUltra is a versa

    12/15/25 4:05:00 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Higgins John L bought $107,707 worth of shares (77,261 units at $1.39), increasing direct ownership by 3% to 2,929,148 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    11/10/25 8:30:36 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Cochran Jennifer R. bought $45,600 worth of shares (30,000 units at $1.52), increasing direct ownership by 26% to 145,274 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    5/15/25 4:02:17 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Love Steven bought $36,500 worth of shares (25,000 units at $1.46), increasing direct ownership by 188% to 38,333 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    5/14/25 5:04:09 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on OmniAb with a new price target

    RBC Capital Mkts initiated coverage of OmniAb with a rating of Outperform and set a new price target of $6.00

    11/29/23 7:31:15 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    The Benchmark Company initiated coverage on OmniAb with a new price target

    The Benchmark Company initiated coverage of OmniAb with a rating of Buy and set a new price target of $8.00

    4/21/23 7:43:22 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Craig Hallum initiated coverage on OmniAb with a new price target

    Craig Hallum initiated coverage of OmniAb with a rating of Buy and set a new price target of $10.00

    4/13/23 9:08:06 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Financials

    Live finance-specific insights

    View All

    OmniAb to Report Fourth Quarter 2025 Financial Results on March 4

    OmniAb, Inc. (NASDAQ:OABI) will report financial results for the quarter and year ended December 31, 2025, after the close of the U.S. financial markets on Wednesday, March 4, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss fourth quarter 2025 financial results and business updates       Date:   Wednesday, March 4, 2026       Time:   4:30 p.m. Eastern time (1:30 p.m. Pacific time)       Phone:   U.S. (800) 549-8228    

    2/19/26 8:00:00 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies

    First and only transgenic chicken platform engineered to express ultralong CDRH3 domains on a human antibody framework broadens therapeutic opportunities beyond conventional antibodies OmniUltra Virtual Investor Event begins at 5:00 p.m. Eastern time today OmniAb, Inc. (NASDAQ:OABI) announces the launch of its new OmniUltra™ platform, the industry's first and only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at the 2025 Antibody Engineering & Therapeutics (AET) Conference underway in San Diego. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215018419/en/ OmniUltra is a versa

    12/15/25 4:05:00 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OmniAb to Hold OmniUltra Virtual Investor Event on December 15

    OmniAb, Inc. (NASDAQ:OABI) today announced it will hold a virtual investor event to showcase the launch of OmniUltra™ on Monday, December 15, 2025, beginning at 5:00 p.m. Eastern time. The event is expected to last approximately one hour and will include a review of OmniAb's newest technology offering, OmniUltra, the industry's only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework. Management will provide an overview of this innovative and pioneering technology platform, its market use and applications, as well as its strategic importance to the business. Conference Call and Webcast Information What:   OmniUltra Launch Virtual Investo

    12/4/25 4:05:00 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by OmniAb Inc.

    SC 13G/A - OmniAb, Inc. (0001846253) (Subject)

    11/14/24 4:06:53 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13D/A filed by OmniAb Inc.

    SC 13D/A - OmniAb, Inc. (0001846253) (Subject)

    7/2/24 5:00:16 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Leadership Updates

    Live Leadership Updates

    View All

    OmniAb Appoints Steve Love to its Board of Directors

    OmniAb, Inc. (NASDAQ:OABI) today announced the appointment of Steve Love to its Board of Directors. Mr. Love has more than 30 years of financial experience including more than 13 years serving in Chief Financial Officer positions, and will serve on OmniAb's Audit Committee as Chair. With this appointment the OmniAb Board returns to seven directors, including five independent directors. "We are delighted Steve has agreed to join the OmniAb Board of Directors and extend a warm welcome," stated John Higgins, OmniAb Board Chair. "Steve's vast financial expertise, technical knowledge and experience leading technology and biotechnology companies will be valuable assets as we grow and expand our

    11/1/23 9:00:00 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care